Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.